ADRB2 and non-small cell lung carcinoma: By blocking the ADRB2 signaling pathway in NSCLC cells in vitro and in vivo, propranolol, a common ADRB2 antagonist, dramatically increased the therapeutic efficacy of VEGFR2-TKIs.